Ubiquitinylated proteins

Document Type

Patent

File Date

10-10-2014

Abstract

A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.

Clinical Institute

Cancer

Specialty

Oncology

Specialty

Earle A. Chiles Research Institute

Location

United States

Comments

Patent Number: 10,226,518

Assignee

UbiVac, LLC (Portland, OR); Providence Health & Science--Oregon (Portland, OR)

Family ID

52809877

Serial Number

14/512,322

Tech ID

13-01-INV

Link to Full Text

Share

COinS